Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KRYS · as of Mar 31, 2025
Ownership Breakdown
316
Institutional Holders
▲ 31 vs Q4
$4.98B
Total Inst. Value
▲ $627.62M vs Q4
29.48M
Shares Outstanding
freeFloat 79.28%
27.62M
13F Shares Held
▼ 156,039 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KRYS largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 4.32M | 15.00% | 15.00% | $779.05B | May 12, 2025 | ▲ 6.8K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.94M | 13.68% | 13.68% | $710.95B | May 2, 2025 | ▼ 90.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.83M | 9.80% | 9.80% | $509.40B | May 9, 2025 | ▼ 53.2K |
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 2.73M | 9.48% | 9.48% | $492.40B | May 15, 2025 | ▲ 102.2K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.23M | 4.26% | 4.26% | $221.18B | May 15, 2025 | ▼ 52.3K |
CAPITAL WORLD INVESTORS biological products, (no diagnostic substances) | 954.5K | 3.31% | 3.31% | $172.09B | May 12, 2025 | ▲ 75.3K |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 737.7K | 2.56% | 2.56% | $133.00B | May 15, 2025 | ▼ 15.5K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 688.5K | 2.39% | 2.39% | $124.13B | May 15, 2025 | ▼ 100.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 612.4K | 2.13% | 2.13% | $110.43B | May 13, 2025 | ▲ 20.8K |
UBS ASSET MANAGEMENT AMERICAS INC biological products, (no diagnostic substances) | 575.5K | 2.00% | 2.00% | $103.76B | May 19, 2025 | ▲ 365.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
19
Increased
+1.27M shares3
New Positions
first time holders27
Decreased
−913.4K shares0
Sold Out
fully exitedNet shares change (top 50)
+352.4K
+1.27M / −913.4K
Net new holders
-5
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KRYS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
23
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 320 | $300.75 | $96.2K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 593 | $302.25 | $179.2K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 247 | $303.17 | $74.9K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 400 | $304.89 | $122.0K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 480 | $305.87 | $146.8K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 1,348 | $307.09 | $414.0K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 12,729 | $307.81 | $3.92M | 1.39M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 3,803 | $308.89 | $1.17M | 1.38M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 2,801 | $309.95 | $868.2K | 1.38M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 2,039 | $310.94 | $634.0K | 1.38M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Krystal Biotech, Inc. (KRYS) is primarily owned by institutional investors, who hold approximately 93.7% of total shares outstanding. Company insiders own approximately 20.72%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Krystal Biotech, Inc. is FMR LLC, holding approximately 4.32 million shares — equal to 15.00% of outstanding shares — as of March 31, 2025.
A total of 316 institutional investors currently hold KRYS stock, with a combined institutional value of approximately $4.98 billion as of the most recent 13F filing period.
Frequently asked questions
KRYS ownershipKrystal Biotech, Inc. (KRYS) is primarily owned by institutional investors, who hold approximately 93.7% of shares. The largest shareholder is FMR LLC with a 15.00% stake. Company insiders hold 20.72%. Data sourced from SEC Form 13F as of March 31, 2025.